key: cord-0264848-ydeuqev7
authors: Joshy, A. S.; Thomas, C.; Surendran, S.; Undela, K.
title: Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19
date: 2022-04-16
journal: nan
DOI: 10.1101/2022.04.15.22273881
sha: 7767c5bf2ecb3f94e131a8483db62d8984f74aae
doc_id: 264848
cord_uid: ydeuqev7

Objective: To evaluate the quality of randomized controlled trials (RCTs) published on Coronavirus Disease-19 (COVID-19) and to investigate the reasons behind compromising the quality, if found. Methods: A systematic literature search was performed in PubMed, Google Scholar, and Cochrane CENTRAL to identify the Randomized Controlled Trails published on Coronavirus Disease-19 between 1st Dec 2019 to 31st Aug 2021. Research articles met with study criteria were included in the study. Assessment of quality of randomized controlled trials was done using modified Jadad scale. Results: 21,259 records of randomized controlled trials were identified through database searching, out of which 90 randomized controlled trials were included in the study and, 34 (37.8%) were of high-quality, 46 (51.1%) were of moderate quality, and 10 (11.1 %) were of low-quality studies. There were 40 (44.4%), 38 (42.2%), and 12 (13.3%) randomized controlled trials published in the early, middle, and late terms with Jadad score 5.12, 5.34, and 5.68 respectively (P=0.52). When comparing the blinding status, appropriate blinding, and methods to evaluate adverse events in randomized controlled trials with modified Jadad score, a significant difference was observed (P<0.001). A significant moderate positive correlation was found between the impact factor of the journal and the modified Jadad scale score (R2= 0.48, P<0.001). Conclusion: Findings from our study indicate that accelerated publication of Coronavirus Disease-19 researches along with the fast-track review process has resulted in lowering study quality scores. With the emergence of stronger evidence, Coronavirus Disease-19 clinical studies with lower methodological quality should be revisited. Keywords: COVID-19, Randomized Controlled Trials, Jadad scale, Quality Assessment

City, Hubei Province, China [1] . SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus) is the disease-causing agent of COVID-19. Concerned about the disease's rapid spread, the World Health Organization (WHO) declared it a pandemic on March 11, 2020. As of January 27, 2022, WHO had confirmed 364,191,494 COVID-19 cases, with 5,631,457 deaths [2] , and Omicron, a novel SARS-CoV-2 variation of concern, has been reported [3] .

Since January 2020, the scientific community has responded enthusiastically to the COVID-19, with information being released at a breakneck pace. As of the time of writing, ClinicalTrials.gov had 7,047 trials registered while WHO's International Clinical Trial Registry Platform has 12,508 trials related to COVID-19 [4] . Rapid progression of the COVID-19 pandemic combined with a lack of available knowledge to guide clinical decision-making is the reason for this exponential increase in the publication of research articles on COVID-19, in the past year [5] . WHO is bringing together scientists and global health professionals from all over the world to speed up research and development, as well as set new norms and standards to manage the coronavirus pandemic and to give proper care to the infected individuals. However, the reliability of the findings of these studies depends on the quality of the research.

The randomized controlled trial (RCT) is the recognized gold standard in clinical research and is thought to produce the best level of evidence for clinically assessing competing interventions, followed by clinical trials. RCT findings are used in Evidence-Based Medicine (EBM) because they are built on an objective, scientific, and systematic study design [6] . The peer-review and fast-track publication process may have inadvertent effects, leading to flawed methodology, and poor quality of findings on COVID-19 [7] . The COVID-19 pandemic's urgency and severity pose both challenges and possibilities for practitioners interested in using EBM [8] and indeed the low quality of published RCTs are thrones in the road of EBM practice.

In a methodological review on the quality of COVID-19 research, authors evaluated the quality of observational studies (cohort and case-control studies), descriptive studies (caseseries), and RCTs published in selected journals [9] . A study reported by Jung et.al.

concluded that there were methodological and reporting issues in the articles published on COVID-19 in major clinical journals, that can result in compromising the utility of the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

This is a retrospective quality assessment study. Research articles were included in the study based on the following inclusion and exclusion criteria. Full-text articles of RCTs conducted either for the prevention, diagnosis, management, and treatment of COVID-19 and which were published in the English language from 1 st December 2019 to 31 st August 2021were included in the study. All the in-vitro or in-vivo studies, descriptive studies (Case series, Case reports, Ecological studies, Descriptive cross-sessional studies), observational cross-sessional studies, non-randomized controlled trials, studies unavailable in the electronic form and conference abstract, and some other studies (Study protocols, post hoc analyses, brief reports, study design & rationale, letters, and correspondence) were excluded from our study.

The electronic databases such as PubMed, Google Scholar, and Cochrane CENTRAL were search strategy can be found in the supplementary appendix (S1).

The author (AJ) independently screened the titles and abstracts of the search results and will code them as either 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full text study reports of all potentially eligible studies. Two review authors . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.15.22273881 doi: medRxiv preprint (AJ and SS) independently assessed these for inclusion and recorded the reasons for the exclusion of ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third review author (KU).

Research articles that met the study criteria were included in the study and data extraction was performed using Microsoft Excel. The following study characteristics were extracted from the included studies (if applicable); the title of the article, name of the journal, name of the authors, name of the corresponding author, name of the corresponding author's institution, name of the publisher, country in which the study was conducted, type of the study design, year of publication, volume number, issue number, page number of the article and the information required for quality assessment of the articles.

The quality of RCTs was assessed using the Modified Jadad scale (also known as the Oxford quality scoring system). Using this scale, studies were scored according to the presence of six features of RCTs, like randomization, blinding, withdrawals or dropouts, inclusion or exclusion criteria, statistical analysis, and the method used to assess the adverse events. Scale scores ranging from zero to eight [11,12] Two reviewers (AJ and SS) have independently assessed the quality of included studies using the Modified Jadad Scale (Supplementary appendix S2). Disagreements between the authors were resolved by consensus with a third reviewer (KU). Based on scores obtained from the scale, studies were categorized into highquality (with a score of 6-8 points), moderate quality (4-5 points), or poor-quality (<4 points) out of a total score of 8.

The studies were divided into three terms: Early (2019 December to 2020 July), mid (2020 August to 2021 January), and late (2021 February to 2021 August). Counted data are described by a number and percentage. The scores obtained by Jadad score were compared and analyzed using one-way analysis of variance test whereas different quality article ratio was analyzed by chi-square test. In addition, the comparisons of different factors influencing the quality of the studies were analyzed using the Student t-test. SPSS v.22.0 was used for all statistical analysis and a P-value of <0.05 was considered statistically significant.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; Out of 90 RCTs, 34 (37.8%) were of high-quality, 46 (51.1%) were of moderate quality, and 10 (11.1 %) were of low-quality studies ( Table 1 ). According to the Jadad scale, 26 RCTs (28.9%) reported blinding, whereas only 22 (24.4%) reported adequate blinding. Only 36 (40.0%) of the 90 RCTs were reported with methodologies to assess adverse events ( Table 2 ).

There were 40 (44.4%), 38 (42.2%), and 12 (13.3%) papers published in the early, middle, and late terms, respectively. The Jadad score for the early, mid, and late terms were 5.12±1.67, 5.34±1.32, and 5.68±1.50 respectively (P=0.52). The number of high-quality articles for the early, mid, and late terms is 12 (30.0), 14(36.8), and 8(66.7) respectively.

There was no significant difference observed between the number of different quality studies and different publication terms (P=0.097, Table 3 ).

It was noted that there was a statistically significant difference in the mean modified jaded scale score and number of studies by blinding status in the trials (P<0.001). Similarly, in trials with and without appropriate blinding, the mean modified Jadad scale was 7.25±0.80 and 4.59±1.01, respectively, with the difference in the score is statistically significant (P<0.001). There was also a significant variation in the number of RCTs in different quality levels and appropriate blinding (P<0.001). The mean modified Jadad scale score in RCTs mentioned with and without methods to assess adverse events were 6.12±1.43 and 4.65±1.22 respectively (P<0.001; Table 4 ). There was a positive correlation noticed between the impact factor of the journal and the modified Jadad scale score (R2= 0.48), which was significant at the level of P<0.001.

In this review of methodological quality, COVID-19 clinical research articles were found to have a methodological flaw. Our findings support those of Quinn TJ et.al., who assessed the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We also investigated the impact of blinding and appropriate blinding in the COVID-19 RCTs, as well as their effects on study quality. We observed that there was a smaller number of the research reported with blinding and appropriate blinding, which significantly lowers the study quality. Blinding is a critical methodologic component of RCTs that helps to reduce bias and enhance the validity of the results. Since COVID-19 is a pandemic and RCT findings might impact clinical decision making, if participants are not blinded, their behavior in the trial and responses to subjective outcome measures may be influenced [104] .

During the first wave of COVID-19, travel bans, quarantine, and stay-at-home measures were enacted, which were the principal barriers to doing efficient COVID-19-related research during the pandemic. The greatest concern during the clinical study was the threat of transmission of the COVID-19 infection not only to the participants but also to the researchers. Because of the small number of participants, the study had drawbacks such as a . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.15.22273881 doi: medRxiv preprint lack of power. To circumvent this hurdle, telemedicine, home medication delivery, webbased randomization, and online questionnaires were used to enroll participants in the trial [5] . However, findings of our results show that these methods resulted in the inadequacy of follow-up of participants, smaller sample size, and shorter study duration of the clinical trial, which may result in compromising the quality of the studies.

One of our study's strengths is that we included all RCTs published on the prevention, diagnosis, treatment and management of COVID-19 from December 2019 to August 2021, and we used validated and standardized scales for quality evaluation, such as the modified Jadad scale.

Our study has certain drawbacks as well. Other quality evaluation criteria, such as sample size computation, sex reporting, and ethical approval, were not examined, and these scales can only assess methodology without regard for causal language.

In conclusion, we observed that the quality of RCTs published on COVID-19 during the pandemic has compromised. According to our findings, the expedited publishing of COVID-19 research, along with the faster review procedure, has resulted in lower study quality scores. Lack of quality can ultimately result in unreliable evidence, which will affect evidence-based clinical practice. So, there should be the adaptation of more reliable and costeffective well-designed methods for conducting clinical trials without sacrificing data quality, ethics, safety, and efficacy and this should be a lesson learned from this catastrophe. With the emergence of stronger evidence, COVID-19 clinical studies with lower methodological quality should be revisited.

None. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. 

Coronavirus disease 2019 (COVID-19): A literature review

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard

Technical Advisory Group on Virus Evolution. Update on Omicron

World Health Organisation. International Clinical Trials Registry Platform. Search Portal

Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic

Systematic reviews in health care: Assessing the quality of controlled clinical trials

COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine

Evidence-based medicine and COVID-19: what to believe and when to change

Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-tomoderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

Impact of aerosol box on intubation during COVID-19: a simulation study of normal and difficult airways

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

Efficacy of surgical helmet systems for protection against COVID-19: a double-blinded randomised control study

Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial

Dexamethasone in Hospitalized Patients with Covid-19

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study)

A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics

Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in nonhospitalized patients with coronavirus disease 2019

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study

Interferon β -1b in treatment of severe COVID-19: A randomized clinical trial

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study

The Role of Vitamin C as Adjuvant Therapy in COVID-19

Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

Remdesivir for the Treatment of Covid-19 -Final Report

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Resuscitation of the patient with suspected/confirmed COVID-19 when wearing personal protective equipment: A randomized multicenter crossover simulation trial

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19